Loading
Life sciences · Journal article
International Journal of Cancer · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Immune checkpoint inhibitors such as anti–PD‐1 antibodies are essential in cancer therapy. Emerging data suggest that lower doses may be effective and more economical, though further evidence is needed. We conducted a retrospective study at Centre Léon Bérard to assess the efficacy and safety of low‐dose nivolumab (20 mg every 3 weeks) in patients with advanced cancer, mainly squamous cell carcinomas (SCC). Between 2023 and 2024, 53 patients were treated, with a median age of 74 years; 39.6% were over 80. Most were male (64%) and had ECOG ≥ 2 (69.9%). Primary tumor sites included cutaneous SCC (34%), head and neck SCC (32%), and soft tissue sarcoma (15%). After a median follow‐up of 8.3 months, median overall survival was 7.5 months. The objective response rate (ORR) was 20.8%, driven by the SCC subgroup; no responses were observed in non‐SCC histologies, in patients with prior ICI exposure, or beyond the second line of treatment. Among IO‐naïve SCC patients treated in first or second line ( n = 22), ORR was 50%. Toxicity was manageable: 18.7% experienced immune‐related adverse events, with only 3.7% grade 3. Low‐dose nivolumab demonstrates encouraging efficacy and tolerability in a frail population, supporting its potential role in resource‐limited settings. Prospective trials are warranted to confirm these findings in broader populations.